Introduction
Methylation of CpG islands in promoter region of genes is due to enzymatic addition of a methyl (CH 3 ) group at the carbon 5 position of cytosine and has been shown to inhibit gene transcription. 1 This enzymatic reaction is mediated by DNA methyltransferases (DNMTs: DNMT1, 3a and 3b) that utilize s-adenosyl-methionine (SAM) as a methyl donor. While DNMT3a and 3b are important to establish novel methylation sites on nascent DNA, DNMT1 plays a critical housekeeping role in maintaining established patterns of DNA methylation in dividing cells. 2 DNMTs have recently been found to be overexpressed in human acute myeloid leukemia (AML) and solid tumors, thereby supporting a role of these enzymes in the development and maintenance of the neoplastic phenotype. 3, 4 Inhibition of DNMT1 by antisense or shRNA oligonucleotides or nucleoside analogs [e.g., 5-aza-2'-deoxycytidine (decitabine)] induces DNA hypomethylation and reactivation of hypermethylated tumor suppressor genes in leukemia cells. [5] [6] [7] [8] [9] [10] [11] This ultimately restores normal patterns of cell proliferation, differentiation and apoptosis, which in turn leads to a significant antitumor activity.
To date, two hypomethylating nucleoside analogs (decitabine and 5-azacitidine, referred to thereafter as azanucleosides) have been approved by the FDA for the treatment of myelodysplastic syndromes (MDS) and are currently in clinical trials for other types of cancer. 12, 13 An accepted mechanism for the antitumor activity of these agents is their incorporation into newly synthesized DNA strands followed by covalent binding, sequestration and depletion of the DNMT enzymes. 12, 13 Clinical responses to only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From -4 -4 azanucleosides, however, appear to be restricted to a minority of hematopoietic malignancies, which are characterized by a relatively high proliferative cell fraction. 14 Thus, development of novel hypomethylating compounds with mechanisms of action distinct from azanucleosides may broaden the therapeutic toolbox targeting epigenetic aberrations in human cancer.
Recent studies suggest that DNMT1 expression is tightly regulated during normal cell growth, and its transcription is modulated by the Sp1 protein in mice. 15 Sp1 is a ubiquitous zinc finger transcription factor that binds GC-rich cis-acting elements
[(G/A)(G/A)GGCC(G/T)(G/A)(G/A)]
in the promoter region of inducible genes. 16 The complexity of the regulatory functions mediated by Sp1 can be explained by a variety of posttranslational modifications (i.e., ubiquitination, glycosylation, phosphorylation) of this protein 16, 17 and/or its physical interaction with other transcription factors, such as those of the NF-κB family 18, 19 that are constitutively activated in AML and controlled by the proteasomal degradation. 20, 21 The 26S ubiquitin-proteasome, formed by the 20S core complex and the 19S regulatory particle, is present in both the cytoplasm and the nucleus of all eukaryotic cells [22] [23] [24] [25] [26] [27] and modulates both the levels and functions of many proteins involved in cell cycle progression, differentiation, apoptosis and adhesion to the microenvironment. 22, [27] [28] [29] [30] [31] The proteolytic activity of 26S proteasome also plays a key role in regulating gene transcription by modulating co-activator recruitment, RNA transcriptional elongation, and protein posttranslational modifications. 32, 33 Disorders in ubiquitin-dependent only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From proteolysis appear to be integral to the neoplastic phenotype and newly developed inhibitors of the proteasome system have been demonstrated to effectively induce apoptosis in malignant cells. [34] [35] [36] [37] [38] Bortezomib, the first proteasome inhibitor approved by the FDA for clinical use in multiple myeloma, is a dipeptidyl boronic acid that reversibly inhibits proteasome activity via formation of a pseudotetrahedral complex between the threonine aminoterminal group and the boronic acid pharmacophore. 38 It has been shown to inhibit NF-κB activation by blocking the ubiquitination and proteasomal degradation of the endogenous NF-κB inhibitor I-κB. 35, 39 We postulated that exposure to bortezomib may cause disruption of the NF-κB and Sp1 interplay, leading in turn to DNMT1 downregulation and DNA hypomethylation. Consistent with our hypothesis, we demonstrated here, for the first time, that bortezomib is a potent inhibitor of DNA methylation in malignant cells by interfering with Sp1/NF-κB DNA binding activity, which in turn results in decreased DNMT1 expression, DNA hypomethylation and transcription of methylation-silenced genes. These findings support bortezomib as a novel, nonazanucleoside therapeutic agent to target aberrant DNA hypermethylation in cancer.
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Materials and Methods

Plasmid and cell lines
Construction of the human Sp1 in EBV/retroviral hybrid vector (Pinco-Sp1) was established as previously described. 40 Retroviral infection to obtain Pinco-Sp1 or Pinco alone stably expressed in 293T cells was performed as previously reported. 41, 42 and NF-κB (p65) (Cell Signaling technology, MA).
Proteasome inhibition assay
MV4-11 cells were incubated with 60 nM of bortezomib for indicated time and stored at -80°C. A spectrofluorometric assay was used to assess the proteasome activity based on a previously described method. 45 
In vivo xenograft models
Athymic nu/nu mice were purchased from Charles River (Wilmington, MA). Four to six week-old animals (n=3 to 5) 
Quantification of global DNA methylation
DNA was prepared using a DNeasy tissue kit (QIAGEN Science, Maryland), and hydrolyzed as previously described. 46 The hydrolyzed DNA was analyzed for DNA methylation by LC-MS/MS as previously described.
47
Electrophoretic mobility-shift assays (EMSAs) and antibody-supershift assays 
Sp1 protein binds to the DNMT1 gene promoter in human cancer cells
It has been reported that DNMT1 promoter activity is regulated by the Sp1 zinc finger protein in murine cells. 15 Analysis of the human DNMT1 promoter identified four putative binding sites for the transcription factor Sp1 (data not shown). Three double stranded DNMT1 promoter probes, which spanned different regions of the DNMT1 only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From promoter containing Sp1 binding sites, were generated for DNA-protein interaction studies. In electrophoretic mobility shift assays (EMSAs) with nuclear (N) or total (T) lysates from MV4-11 cells, the use of all three probes yielded slower migrating DNAprotein complexes (Fig. 2A, lane 3 and 4) . The specificity of DNA binding was demonstrated by competition with 20-fold excess unlabeled DNMT1 promoter probes ( Fig. 2A, lane 2) . In addition, unlabeled DNA oligos containing the consensus Sp1 binding site efficiently competed away protein-binding to 2 out of 3 probes (i.e., DNMT1-Sp1-1, and -2 probes), supporting the specific interaction of DNMT1 promoter with Sp1 protein (Fig. 2A, lane 1) . These results indicated that Sp1 protein was enriched on DNMT1 gene promoter. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From C1, supporting that NF-κB was part of the protein binding complex in MV4-11 cell lysates and suggesting that NF-κB interplays with Sp1 for DNMT1 transactivation.
The physical interaction between Sp1 and NF-κB was further supported by the observation that Sp1 was co-immunoprecipitated with NF-κB (p65) in untreated MV4-11 cells (Fig. 2C) . In contrast, Sp1 and NF-κB did not co-immunoprecipitate in bortezomib treated cells (Fig. 2C) , indicating that bortezomib disrupted this protein-protein interaction. Furthermore, bortezomib exposure significantly reduced the DNA binding activity of both Sp1 and NF-κB, as shown in the EMSA experiments using consensus DNA binding probes for these two proteins (Fig. 2D, lane B) . In contrast, the DNAprotein complex remained intact in cells untreated (Fig. 2D , lane C) or treated with decitabine (Fig. 2D, lane D) .
Changes in Sp1 protein levels correlate with changes in DNMT1 transcription
To further support the hypothesis that the Sp1/NF-κB complex co-participates in DNMT1 transcriptional activation, the Sp1 gene was cloned into a viral vector (Pinco) and stable Sp1 expression in 293T cells was established. Increased levels of DNMT1 protein, but not histone deacetylase 1 (HDAC1), were observed in cells over-expressing Sp1, when compared to cells transfected with the empty vector (Fig. 3A) . Notably, over-expression of NF-κB (p65) in 293T cells also augmented the expression of DNMT1 protein (Fig.   3B ). Treatment of MV4-11 cells with mithramycin A, an inhibitor of Sp1 binding activity, 50 led to dose-dependent reduction of DNMT1 levels (Fig. 3C) . Moreover, both DNMT1 and Sp1 protein levels were decreased in mithramycin A-treated AML primary only.
For (Fig. 3D) . Finally, when Sp1 expression was knocked down by using Sp1 shRNA, a concurrent decrease in DNMT1, but not HDAC1 (Fig. 3E) , was observed, thereby supporting a role of Sp1 protein in regulating DNMT1 expression.
Bortezomib-induced inhibition of the 26S proteasome represses Sp1 expression and abrogates its DNA binding activity
We next studied whether bortezomib-induced proteasome inhibition alters Sp1 protein expression and activity. MV4-11 and Kasumi-1 cells were exposed to bortezomib (0, 1, 6, 20, 60 and 100 nM) for 24 hrs and Sp1 expression was examined. Bortezomib treatment induced a significant decrease in Sp1 protein level in a dose-dependent manner (Fig. 4A) . Importantly, when the activity of bortezomib was tested in vivo, we observed >80% down-regulation of Sp1 levels in tumors from MV4-11 xenografts following 48 hrs treatment with a single dose (2 mg/kg) of bortezomib, compared to tumors from untreated controls (P<.0001, pairwise t test) (Fig. 4B) . No toxicity was observed in the treated animals.
To determine the effect of bortezomib on the Sp1 binding to the DNMT1 promoter, EMSAs were performed with nuclear extracts from MV4-11 cells treated with bortezomib (60 nM for 24 hrs). As shown in Fig. 4C , bortezomib decreased the Sp1 protein binding to the DNMT1 promoter, while no obvious alteration of the Sp1 DNA binding was observed in decitabine treated cells. In addition, Western blot analysis on the same extracts showed that bortezomib decreased Sp1 protein expression (data not
Bortezomib causes down-regulation of DNMT1 gene expression
As Sp1 interacts with NF-κB to transactivate DNMT1, and bortezomib negatively affects protein levels were significantly decreased in a dose-and time-dependent fashion ( Fig.   5A and B, right panels). In contrast, we did not observe significant changes in the levels of control proteins (i.e., HDAC1), supporting a specific activity of bortezomib on DNMT1 expression. DNMT1 mRNA and protein levels were also decreased in other bortezomib-treated hematopoietic and non-hematopoietic cell lines, i.e. Kasumi-1, K562, THP-1, Jurkat, Eol-1, NB4, ML-1 and HCT116 (data not shown). DNMT1 protein levels were found significantly decreased in tumors of mice engrafted with MV4-11 (P=.0001; pairwise t-test) or K562 (P=.026; pairwise t-test) cells and treated with bortezomib when compared to untreated controls ( Fig. 5D and E) . No significant alterations occurred in the levels of other proteins (i.e., HDAC1), suggesting a specific activity of bortezomib on DNMT1 both in vitro and in vivo.
A decrease in DNMT1 transcription correlates with a decrease in global genomic
DNA methylation in vitro and in vivo
Given the inhibitory effects of bortezomib on DNMT1 transcription, we next investigated whether this compound also induced DNA hypomethylation. MV4-11 cells were treated with 20 nM of bortezomib for 24 hrs. Genomic DNA was isolated and hydrolyzed and assessed for levels of global DNA methylation by LC-MS/MS. 47 Approximately 50% reduction in global DNA methylation was observed in bortezomib-treated cells when compared to untreated controls (Fig. 6A ). To test whether this effect could be reproduced in vivo, DNA samples from MV4-11 and K562 xenograft tumors were analyzed by LConly.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From MS/MS. 47 We observed DNA hypomethylation in the tumor cells from bortezomibtreated animals, when compared to untreated controls ( Fig. 6B and C) . This effect correlated with the aforementioned changes in DNMT1 protein levels, suggesting that bortezomib acted as a hypomethylator both in vitro and in vivo through decreasing DNMT1 expression. Very similar results were observed in other leukemia cell lines, i.e.
Kasumi-1 and THP-1 (data not shown). Other anti-cancer drugs with different mechanism of action, such as depsipeptide, trichostatin A (TSA) and 17-allylaminodemethoxygeldanamycin (17AAG), failed to induce global DNA hypomethylation, supporting a specific effect of bortezomib on cellular epigenetic profiles.
Bortezomib treatment increases expression of epigenetically silenced genes
A recent report showed that RIL, a LIM domain gene mapping to 5q31.1, is frequently methylated and silenced in several cancer and leukemia cell lines, and decitabine treatment restores RIL expression. 51 Therefore, in order to assess whether bortezomib could re-activate methylation-silenced genes, we used HCT116 and ML-1 cells, in which the RIL gene is highly methylated. 51 In both cell lines, RIL expression was significantly increased by bortezomib exposure, i.e. ~2 folds at 3 hrs and >5 folds at 12 hrs in HCT116 cells (Fig. 7A, left panel) and ~4 folds at 24 hrs and >15 folds at 48 hrs in ML-1 cells (Fig. 7A, right panel) , compared with untreated controls. DNMT1 protein levels were concomitantly down-regulated by bortezomib in both cell lines (Fig. 7B) . In order to investigate the methylation status of RIL gene promoter after bortezomib treatment, genomic DNA from bortezomib-treated ML-1 cells was digested with the restriction only.
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Following digestion, DNA was analyzed by RT-PCR using primers specific to the RIL gene promoter. Efficient digestion by Hpa II or Bstu I leads to weaker amplification bands in hypomethylated or hypermethylated RIL promoters, respectively, when compared to undigested controls. Consistent with the re-expression data and similar to decitabine-treated controls, these data provide the evidence that the RIL gene promoter is hypomethylated in ML-1 cells following bortezomib treatment (Fig. 7C) .
Discussion
The ubiquitin-proteasome system regulates several fundamental cellular processes, such as cell cycle progression, differentiation and apoptosis. 22 The proteasome inhibitor bortezomib inhibits the 26S proteasome machinery via the formation of a pseudotetrahedral complex and is postulated to influence gene expression by affecting the proteosome-mediated degradation of transcription factors such as NF-κB. 22 Recent studies indicated that in the mouse DNMT1 is a target for the zinc finger protein Sp1, 15 which also serves as a broad transcriptional co-regulator with NF-κB. 18, 19 Since NF-κB is constitutively activated 20, 21 and DNMT1 is frequently overexpressed in AML cells, 3, 4 we hypothesized that epigenetic regulatory pathways dependent on DNMT1 in cancer cells could be modulated by bortezomib-induced inhibition of the 26S proteasome, possibly by interfering with Sp-1/NF-κB -mediated transactivation. 22 In order to test our hypothesis, we first studied the effect of bortezomib treatment on Sp1.
We found that inhibition of 26S proteasome by bortezomib leads to depletion of Sp1 in vitro and in vivo, disruption of the Sp1/NF-κB (p65) physical interaction and inhibition of Sp1 DNA binding activity. Notably, levels of NF-κB (p65) are not obviously altered by bortezomib treatment, although drug exposure affects the activity of this protein as supported by a decrease in DNA binding and disruption of the Sp1/NF-κB coimmunoprecipitation complex. It has previously been reported that the expression and functional activity of Sp1 is regulated by posttranscriptional modifications and at least in part by proteasomal degradation. 16, 17 To our knowledge, however, this is the first report that bortezomib treatment induces Sp1 depletion. Whether this is a direct result of only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From bortezomib-mediated inhibition of the 26S proteasome or relates to indirect interference of this drug on specific phases of the cell cycle that are preferentially associated with Sp1 expression remains to be fully elucidated. Nevertheless, our data add another target to a long list of proteins whose changes in expression or activity mediate bortezomib antitumor effect. 52 We next demonstrated that bortezomib induces a marked decrease in DNMT1 transcription, and this in turn leads to global DNA hypomethylation and re-expression of epigenetically silenced genes. Transactivation of DNMT1 by Sp1 has previously been reported. Kishikawa et al. showed that Sp1 binds to the DNMT1 gene promoter, and forced Sp1 expression in Drosophila SL2 cells, which lack the Sp family of transcription factors, enhances transcription of DNMT1 gene promoter. 15 We reported here that in human cancer cells, DNMT1 is co-regulated through both Sp1 and NF-κB (p65). For
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This suggests that interference with 26S complex activity by bortezomib could result in generalized transcriptional down-regulation. In our experiments, however, the effect of bortezomib on DNMT1 expression appeared specific, as levels of other proteins (i.e., HDAC1) remain unchanged following drug exposure. Interestingly, a paradoxical increase in DNMT1 expression was observed in cells exposed to bortezomib at very low doses (i.e., 1 and 6 nM) or for very short time (i.e., 1 hr) (Fig. 5A and B) . Although this observation remains to be fully elucidated from a mechanistic standpoint, it is possible that at very low doses or short duration of bortezomib exposure, mechanisms that interfere with the hypomethylating effects of this drug might be activated (e.g., transient increase in ubiquinated, but active Sp1). Furthermore, these data underscore the importance for dose optimization and selection of optimal time points for correlative studies that intend to demonstrate the hypomethylation activity of bortezomib in upcoming clinical trials.
Bortezomib treatment ultimately caused global DNA hypomethylation, both in vitro and in vivo, and restored the expression of the RIL gene in HCT116 and ML-1 cells, where this gene is silenced via hypermethylation. 51 Consistent with these results, we also showed that bortezomib induces hypomethylation of the RIL gene promoter. Our study suggests that bortezomib induces hypomethylation through pathways of DNMT1 depletion that are different from those of azanucleosides. Goshal et al. showed that one of the possible hypomethylating mechanisms of the azanucleosides is DNMT1 depletion via covalent trapping of the protein on DNA followed by selective proteasomal degradation. 55 In contrast, we showed that bortezomib as a single agent induces DNMT1
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Altogether, these data support bortezomib as an effective non-azanucleoside hypomethylator and a novel strategy for broadening epigenetic-targeting approaches to azanucleoside-resistant malignancies. Of note, the development of bortezomib as an epigenetic-targeting agent in human cancer will be facilitated by the fact that this is an already FDA-approved agent with a known and relatively benign toxicity profile.
Finally, we showed here that bortezomib has hypomethylating activity in AML, a disease where hypermethylation-mediated gene silencing is a well characterized event and found 1 µg DNA from bortezomib treated or untreated ML-1 cells were digested by Hpa II or Bstu I and PCR were performed by using primers specific for RIL gene promoter. Note:
Hpa II, no digestion, then hypermethylated; Bstu I, no digestion, then hypomethylated.
